tbuckley/cabot-search huggingface dataset:
Mammography screening: please don't be vague, tell me when I should come!
Authors: Paolo Giorgi Rossi, Livia Giordano
Journal: The Lancet Oncology (2017)

In The Lancet Oncology, Prue Allgood and colleagues1 report the results of a large population-based trial of second timed appointments for non-attenders of breast cancer screening in England. Their findings show that this policy is effective in improving participation compared with an invitation letter with a telephone number to call to book a new appointment (2861 [22%] of 12 807 women in the intervention group participated in breast cancer screening within 90 days of the first offered appointment compared with 1632 [12%] of 13 247 women in the control group; relative risk 1·81 [95% CI 1·70–1·93], p<0·0001).
Toxicogenomic analysis of aristolochic acid-induced epithelial injury and carcinogenesis
Authors: Shujuan Gao, Kathleen Dickman, Huan Dong, Frederick Miller, Jiri Zavadil, Arthur P. Grollman
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

1905 

Aristolochic acid (AAI) is a naturally occurring herbal toxin whose cumulative ingestion results in tubulointerstitial fibrosis and leads to end-stage renal failure. Patients with aristolochic acid-associated nephropathy (AAN) also exhibit high prevalence of upper urothelial carcinomas. We used an in vivo model of AAN to explore molecular and cellular mechanisms underlying genotoxic and cytotoxic effects of AAI. The susceptible mouse strain C3H/He was treated by daily intraperitoneal administration of AAI. Accumulation of DNA adducts in the renal cortex was demonstrated by 32P-post-labeling methods. Histopathological evaluation revealed progressive cell death (necrosis/apoptosis), significant inflammation and fibrosis starting on day 3. RNA extracted from the renal cortex was subjected to DNA array analyses (7 time-points with time-matched untreated animals as controls) using Affymetrix mouse genome 430A 2.0 arrays. Rigorous statistical filtering and gene ontology (GO, biological process) representation analyses revealed extensive transcriptional reprogramming including rapid mobilization of genes involved in p53-dependent DNA damage and repair responses, cell cycle arrest and apoptosis (Cdkn1a/p21, Pcna, Gadd45b/g, Ercc1, Rad51), inflammatory/immune response (monocyte chemotactic proteins Ccl2/Mcp1 and Ccl8/Mcp2, Cxcl1/Gro1, C3), and fibrogenic mechanisms implicating TGF-β directed epithelial-mesenchymal transition (EMT) in the tubular epithelia (Tgfb1, Tgfbr1, Fos, S100a4/Fsp1, Col1a1, Col3a1, Fn1, Ctgf, Dcn, Mmp2). Next, we used Affymetrix human genome U133A 2.0 arrays to analyze primary (HKPTC) and immortalized (HK-2) human proximal tubular cells treated by AAI. We observed broad overlap between the mouse model and cultured human cells in both rapid DNA adduct formation and expression patterns involving key gene orthologs, supporting our primary hypothesis that proximal tubular cells are the primary target in AAN. In conclusion, our toxicogenomic approach provides novel insights into molecular networks underlying pathogenesis of AAN and is being extended to expression profiling of carcinogenic effects of AAI in murine urothelium.. (Research supported by NIH grant ES 04068)
An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Authors: Yan W. Asmann, Chen Wang, Brian M. Necela, Xianfeng Chen, Jean-Pierre A. Kocher, Matthew J. Maurer, Thomas Matthew Habermann, Susan L. Slager, Andew L. Feldman, Ahmet Dogan, Anne Novak, James Robert Cerhan, Edith A. Perez, E. Aubrey Thompson
Journal: Journal of Clinical Oncology (2014)

e22171 Background: Structural variants (SV) including large copy number aberrations (CNV), translocations, inversions, and large insertions and deletions (INDEL) play a critical role in tumorigenesis and progression. In fact, we now know that tumors can be categorized according to the size of mutations harbored. In several cancers, including ovarian and breast cancer, the large structural mutations, rather than single site mutations, play a dominate role in tumor etiology. Therefore, it's critical to implement reliable algorithm for the detection of structural variants in DNA sequencing data. Mate-pair sequencing is a protocol specifically implemented for detection of the whole-genome level structural variants. It requires less sequencing depth therefor is cost effective, and enables the detection of CNVs, translocations, and inversions simultaneously. However, so far there has been no reliable bioinformatics pipeline for the analyses of the mate-pair sequencing data. Methods: Our novel algorithm, the SnowShoes-SV, is an exhaustive search algorithm designed specifically for mate-pair DNA sequencing data analyses. It calls the SVs based on disconcordant read pairs. The false SVs are filtered according to the following criteria: (i) the number of the supporting read pairs; (ii) the lack of reads from control data that implicate SV at the same region; (iii) the mappability and uniqueness of the region based on data from the ENCODE project; (iv) consistencies of the mapping orientations of the supporting read pairs; (v) the similar sizes between sequencing library and the two end read clusters. Results: Using a set of samples previously genotyped by aCGH, the SnowShoes-SV successfully detected all known CNVs and other SVs. It also identified copy number neutral translocations and inversions previously not identified by aCGH. In addition, the algorithm nominated novel SVs which are to be validated by PCR. Conclusions: SnowShoes-SV is a highly sensitive and specific algorithm for SV detection from the mate-pair DNA sequencing data.
Keynote Address: <i>When Breath Becomes Air</i> —As Physician Becomes Patient
Authors: Lucy Kalanithi, Heather Wakelee, Robert W. Carlson
Journal: Journal of the National Comprehensive Cancer Network (2017)

As part of the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, Lucy Kalanithi, MD, wife of now-deceased best-selling author Paul Kalanithi (When Breath Becomes Air), and Heather Wakelee, MD, Paul's oncologist, discussed-for the first time together in a public forum-Paul's experience of going from a neurosurgery resident to a patient with cancer with a terminal diagnosis. Robert Carlson, MD, moderated the discussion.
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
Authors: Ronghao Wang, Yin Sun, Lei Li, Yuanjie Niu, Wanying Lin, Changyi Lin, Emmanuel S. Antonarakis, Jun Luo, Shuyuan Yeh, Chawnshang Chang
Journal: European Urology (2017)
Fogarty International Center, a Linchpin of Global Health Research
Authors: M.J. Friedrich
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cisplatin, gemcitabine, and vinorelbine (PGV) compared with cisplatin and etoposide (PE) in the first-line treatment of extensive-stage small-cell lung cancer: Two Brazilian institution experience.
Authors: Augusto Akikubo Rodrigues Pereira, Ronnei J F Assis, Emiliano da Costa Pereira, Vladmir C. Lima, Pedro B. Nugue, Jose Rodrigues Pereira
Journal: Journal of Clinical Oncology (2013)

e18548 Background: The standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) has been cisplatin plus etoposide (PE). Phase II studies showed comparable outcomes and less toxicity with platinum-doublets containing gemcitabine or vinorelbine. Aiming to improve response rates without increasing toxicity, we evaluated the combination of cisplatin, gemcitabine plus vinorelbine (PGV) in comparison to PE. Methods: Patients with ES-SCLC, ECOG 0-1, admitted from January 2002 to January 2011 in two brazilian institutions were analyzed. We compared patients treated with PE (cisplatin 80 mg/m 2 D1 and etoposide 100 mg/m 2 D1-D3 every 3 weeks for up to 6 cycles) versus modified PGV (cisplatin 80 mg/m 2 D1, gemcitabine 1500 mg/m 2 D1 and vinorelbine 30 mg/m 2 D1 every 3 weeks for up to 6 cycles). Results: Of 69 patients analyzed, 29 were treated with PGV and 40 with PE. Clinical characteristics were comparable in both groups, except for adrenal metastases that were more frequent in PE group (20% vs. 0%; p=0,02). Overall response and complete response rates with PGV and PE were 75.9% vs. 65.0% (p=0.33) and 6 (20.7%) vs. 3(7.5%) (p=0.15), respectively. Median progression-free survival for PGV and PE was 6.47 and 5.06 months (p=0.37). Median overall survival for PGV and PE was 10.94 months versus 9.65 months (p=0.76). Severe neutropenia was higher with PE versus PGV (57.1% vs. 23.1%; p=0.01). Severe vomiting (38.5% vs. 17.2%; p=0.07) and peripheral neuropathy (15.4% vs. 5.3%; p=0.37) were more common with PGV than PE, although without statistical significance. Conclusions: Modified PGV presented comparable efficacy to standard PE in the first-line treatment of ES-SCLC. Response rates were higher with PGV, but without statistical significance. PGV showed less severe neutropenia than PE, but higher non-significant severe vomiting and neuropathy. Prospective studies with a large number of patients should be provided to confirm these results.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation
Authors: Naoko Tsuyama, Seiji Sakata, Satoko Baba, Yuko Mishima, Noriko Nishimura, Kyoko Ueda, Masahiro Yokoyama, Yasuhito Terui, Kiyohiko Hatake, Masanobu Kitagawa, Naoki Ishizuka, Naoto Tomita, Kengo Takeuchi
Journal: Blood (2017)
COPD研究(SPIROMICS)における亜集団と中間結果のデザイン
Authors: Couper David, Lavange Lisa M, Han MeiLan, Barr R Graham, Bleecker Eugene, Hoffman Eric A, Kanner Richard, Kleerup Eric, Martinez Fernando J, Woodruff Prescott G, Rennard Stephen
Journal: Thorax (2014)
Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland
Authors: Abigail R A Aiken, Irena Digol, James Trussell, Rebecca Gomperts
Journal: BMJ (2017)

<b>Objectives</b>&nbsp;To assess self reported outcomes and adverse events after self sourced medical abortion through online telemedicine. <b>Design</b>&nbsp;Population based study. <b>Setting</b>&nbsp;Republic of Ireland and Northern Ireland, where abortion is unavailable through the formal healthcare system except in a few restricted circumstances. <b>Population</b>&nbsp;1000 women who underwent self sourced medical abortion through Women on Web (WoW), an online telemedicine service, between 1 January 2010 and 31 December 2012. <b>Main outcome measures</b>&nbsp;Successful medical abortion: the proportion of women who reported ending their pregnancy without surgical intervention. Rates of adverse events: the proportion who reported treatment for adverse events, including receipt of antibiotics and blood transfusion, and deaths reported by family members, friends, or the authorities. Care seeking for symptoms of potential complications: the frequency with which women reported experiencing symptoms of a potentially serious complication and the proportion who reported seeking medical attention as advised. <b>Results</b>&nbsp;In 2010-12, abortion medications (mifepristone and misoprostol) were sent to 1636 women and follow-up information was obtained for 1158 (71%). Among these, 1023 women confirmed use of the medications, and follow-up information was available for 1000. At the time women requested help from WoW, 781 (78%) were &lt;7 weeks pregnant and 219 (22%) were 7-9 weeks pregnant. Overall, 94.7% (95% confidence interval 93.1% to 96.0%) reported successfully ending their pregnancy without surgical intervention. Seven women (0.7%, 0.3% to 1.5%) reported receiving a blood transfusion, and 26 (2.6%, 1.7% to 3.8%) reported receiving antibiotics (route of administration (IV or oral) could not be determined). No deaths resulting from the intervention were reported by family, friends, the authorities, or the media. Ninety three women (9.3%, 7.6% to 11.3%) reported experiencing any symptom for which they were advised to seek medical advice, and, of these, 87 (95%, 87.8% to 98.2%) sought attention. None of the five women who did not seek medical attention reported experiencing an adverse outcome. <b>Conclusions</b>&nbsp;Self sourced medical abortion using online telemedicine can be highly effective, and outcomes compare favourably with in clinic protocols. Reported rates of adverse events are low. Women are able to self identify the symptoms of potentially serious complications, and most report seeking medical attention when advised. Results have important implications for women worldwide living in areas where access to abortion is restricted.
Postmarketing Surveillance for Angiotensin-Converting Enzyme Inhibitor Use During the First Trimester of Pregnancy— United States, Canada, and Israel, 1987-1995
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12276: The Changing Landscape of Ventricular Assist Device Utilization in Children Bridged to Transplant: The “Revolution” Begins
Authors: Chet R Villa, Muhammad S Khan, Farhan Zafar, Jonathan W Byrnes, David L Morales, Angela Lorts
Journal: Circulation (2015)

Introduction: Growing clinical experience and innovative implantation techniques have allowed individual pediatric centers to push the boundaries of VAD use. However, data describing the global trends in VAD utilization are lacking. We sought to assess temporal trends in the use of VADS as a bridge to transplant in children across the US. Methods: Children &lt;18 years listed for heart transplant 1/2006-6/2014 who were bridged with a VAD were identified in the UNOS database. Patients were stratified by era (Early: 2006-2010, Current: 2011-2014). Descriptive statistics were used to assess trends. Results: Of 3986 patients listed, 589 (15%) received a VAD as bridge to transplant during the study period. The percentage of patients bridged with a VAD increased in the current era (12% vs. 18%, p&lt;0.001), while both durable cfVAD use and waitlist times increased (Table). Children &lt; 25 kg continue to be bridged to transplant almost exclusively with pulsatile devices while 95% of patients ≥ 25 kg were bridged with a cfVAD in 2014 (Figure). Conclusions: The current era has seen a 1.5-fold increase in the percentage of children bridged to transplant with a VAD as well as a 3-fold increase in the percentage of patients bridged with a durable cfVAD in patients &gt; 25 kg. The emergence of cfVAD technology in an era of increasing waitlist times, raises the prospect of a dramatic increase in the number of children discharged from the hospital while supported with a cfVAD. This underscores the need to rapidly define pediatric specific best care practices in outpatient VAD management.
Abstract 1414: Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Improves Contractility in {alpha}-Adrenergic Stimulated Myocardium
Authors: Claudius Jacobshagen, Swantje Kortlepel, Bernhard W Unsoeld, Harald Kogler, Gerd Hasenfuss, Lars S Maier
Journal: Circulation (2007)

Background - In cardiac myocytes phosphatidylinositol 3-kinase (PI3K) activated signaling pathways are involved in the regulation of various cellular functions such as cell growth, metabolism and s...
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Authors: Véronique Diéras, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E Krop, Kim Blackwell, Silke Hoersch, Jin Xu, Marjorie Green, Luca Gianni
Journal: The Lancet Oncology (2017)
In older men with low testosterone levels and age-associated memory impairment, testosterone did not improve memory
Authors: Calvin Hirsch
Journal: Annals of Internal Medicine (2017)

Source Citation Resnick SM, Matsumoto AM, Stephens-Shields AJ, et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA. 2017;317:717-27. 28241356
Angubindin-1, a novel paracellular absorption enhancer acting at the tricellular tight junction
Authors: Susanne M. Krug, Tomohiro Hayaishi, Daisuke Iguchi, Akihiro Watari, Azusa Takahashi, Michael Fromm, Masahiro Nagahama, Hiroyuki Takeda, Yoshiaki Okada, Tatsuya Sawasaki, Takefumi Doi, Kiyohito Yagi, Masuo Kondoh
Journal: Journal of Controlled Release (2017)
STUDIES ON THE FLEXNER GROUP OF DYSENTERY BACILLI
Authors: Ely Perlman, Walther F. Goebel
Journal: The Journal of Experimental Medicine (1946)

1. The toxicity of killed dysentery bacilli can be ascribed to the somatic antigen. Antibodies to intact dysentery bacilli apparently contain no toxin-neutralizing antibodies other than those which precipitate the purified somatic antigen. 2. The serological properties of dysentery bacilli are determined by the specific somatic antigen. The specificity and cross-reactivity of the somatic antigen are dependent upon the carbohydrate moiety of the molecular complex.
Abstract 266: Truncated Glycogen Synthase Kinase 3β Increases Mitochondrial Fragmentation, Reactive Oxygen Species generation, and Cell Injury
Authors: Stephen Hurst, Jin O-Uchi, BongSook Jhun, Thomas Force, Shey-Shing Sheu
Journal: Circulation Research (2013)

Introduction: Oxidative stress during ischemia reperfusion (IR) injury remains a major obstacle during percutaneous coronary intervention after acute myocardial infarction. It often leads to an increased susceptibility for mitochondria permeability transition pore (mPTP) opening leading to cell death and worsened contractile recovery. Glycogen synthase kinase 3β (GSK-3β) is proposed as one of the key molecules that regulate mitochondrial dysfunction and injury during IR. Oxidative stress increases activation of matrix metalloproteinase 2 (MMP2) and subsequent cleavage (amino acids 1-34) of GSK-3ß to form a constitutively-active truncated form. However, the molecular mechanism underlying how GSK-3β activity controls mitochondrial form/function under oxidative stress condition is not fully understood. Hypothesis: Oxidative stress induces GSK-3ß to form a constitutively-active truncated form through MMP2-mediated cleavage, which leads to increased susceptibility of mPTP opening and activation of cell death signaling. Methods: Using overexpression of full length and truncated GSK-3β fused to GFP in H9C2 cells we determined the effects of GSK-3β on mitochondrial morphology and reactive oxygen species (ROS) generation using confocal microscopy. Activation of cell death signaling was evaluated by cytochrome c release, caspase activation, and GSK-3β activity using Western blotting. Results: Non-transfected and full-length GSK-3ß had comparable mitochondrial networking and morphology whereas cells overexpressing truncated GSK-3ß showed distinct mitochondrial fragmentation and swelling. Similarly, the non-transfected and full-length GSK-3ß overexpressing cells had equivalent levels of ROS whereas the truncated-GSK-3ß overexpressing cells had markedly increased levels of basal ROS that was further enhanced with transient H2O2 treatment. Cells overexpressing truncated GSK-3ß had an increased susceptibility to mPTP opening as measured by cytochrome C release to the cytoplasm when challenged with H2O2. Conclusion: Truncation of GSK-3ß induces increased mitochondrial ROS formation as well as mitochondrial fragmentation that is indicative of mitochondrial damage and an increased susceptibility to mPTP opening.
Genetic Modifiers Identify a High Risk Group for Stroke in Three Independent Cohorts of Sickle Cell Anemia Patients
Authors: Santosh L. Saraf, Titilola S. Akingbola, Binal N. Shah, Xu Zhang, Lewis L. Hsu, Mark T. Gladwin, Roberto F. Machado, Richard S. Cooper, Victor R. Gordeuk, Bamidele O. Tayo
Journal: Blood (2016)